Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report-Reference-Cited by-同舟云学术

Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report

Published:2016-08-19 Issue:4 Volume:35 Page:875-877
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Tardy Magalie P.¹,Gastaud Lauris¹,Boscagli Annick¹,Peyrade Frederic¹,Gallamini Andrea¹,Thyss Antoine¹

Affiliation:

1. Department of Oncology; Antoine-Lacassagne Center, Cancer Research Center; Nice France

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference9 articles.

1. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma;Ansell;N Engl J Med.,2015

2. Toxicities of immunotherapy for the practitioner;Weber;J Clin Oncol Off J Am Soc Clin Oncol,2015

3. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification;Cheson;J Clin Oncol,2014

4. Autoimmune haemolytic anaemia preceding the diagnosis of Hodgkin's disease: a report of two cases and review of the literature;Siddiqui;JPMA J Pak Med Assoc,2009

5. Autoimmune hemolytic anemia and nodular lymphocyte-predominant hodgkin lymphoma: a rare association;Salmeron;Case Rep Hematol,2013

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Predictive Value of Inflammatory Markers, Prealbumin, and Albumin in the Clinical Efficacy of PD-1 Therapy in Advanced Solid Tumor Patients;Advances in Clinical Medicine;2024

2. Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT);Journal of Experimental & Clinical Cancer Research;2023-10-21

3. Atezolizumab-Induced Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia;American Journal of Therapeutics;2023-07-11

4. Case report: A rare case of acute hemolysis in advanced rectal cancer after XELOX and nivolumab treatment: analysis of drug-dependent antibodies;Frontiers in Medicine;2023-05-25

5. Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient’s safety and survival outcome:A systematic narrative appraisal of where we are now!;Transfusion and Apheresis Science;2023-04